Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study

The poly(ADP‐ribose) polymerase‐1/2 inhibitor veliparib is active against tumors deficient in homologous DNA damage repair. The pharmacokinetics and safety of veliparib extended‐release (ER) were evaluated in patients with advanced solid tumors. This phase I study assessed veliparib‐ER up to 800 mg...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Werner, Theresa L., Sachdev, Jasgit, Swisher, Elizabeth M., Gutierrez, Martin, Kittaneh, Muaiad, Stein, Mark N., Xiong, Hao, Dunbar, Martin, Sullivan, Danielle, Komarnitsky, Philip, McKee, Mark, Tan, Antoinette R.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6010916/
https://ncbi.nlm.nih.gov/pubmed/29733524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1488
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados